XML 48 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended 10 Months Ended
Sep. 17, 2021
May 14, 2019
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Mar. 16, 2020
Mar. 11, 2020
Debt Instrument [Line Items]                
Term loans aggregate principal amount     $ 100,000,000   $ 100,000,000      
Adjustments to additional paid-in-capital, warrants issued     1,290,000          
Term Loan                
Debt Instrument [Line Items]                
Debt instrument borrowed amount               $ 25,000,000.0
Debt instrument, additional borrowing capacity amount             $ 25,000,000.0  
Term Loan First Advance                
Debt Instrument [Line Items]                
Final payment of debt         54,300,000      
SVB Term Loan                
Debt Instrument [Line Items]                
Debt instrument, maturity date   May 01, 2024            
Debt instrument, final payment fee percentage   8.25%            
Debt instrument, final payment fee or end of term charge     $ 4,100,000   $ 4,100,000      
Fair value of warrant liabilities   $ 400,000            
Debt issuance costs   $ 200,000            
Debt instrument, interest rate percentage     7.25%   7.25%      
Debt instrument, description         Under the original SVB Term Loan, the monthly payments consisted of interest-only through May 31, 2021. On March 11, 2020, the Company entered into the first amendment and on March 11, 2021, the Company entered into the second amendment (together the “Amendments”) to the SVB Term Loan. Pursuant to the Amendments, the interest-only payment period was initially extended through July 31, 2021, and was further extended until December 31, 2021, after the Company received positive data from its Phase 3 clinical trial in H. pylori infection sufficient to file an NDA with the FDA. The interest-only payment period could have been further extended until November 30, 2022, if the Company would receive positive data from its Phase 3 clinical trial in erosive esophagitis for vonoprazan sufficient to file an NDA with the FDA.      
Debt instrument penalty fee percentage   4.00%            
Warrants expire term   10 years            
Warrants exercisable shares of common stock   16,446            
Aggregate repurchase price of warrants   $ 500,000            
Adjustments to additional paid-in-capital, warrants issued         $ 300,000      
SVB Term Loan | Maximum                
Debt Instrument [Line Items]                
Debt instrument, prepayment fee percentage of outstanding principal amount   2.00%            
SVB Term Loan | Prime Rate                
Debt Instrument [Line Items]                
Debt instrument, basis spread on variable rate   1.75%            
Loan Agreement                
Debt Instrument [Line Items]                
Debt instrument, final payment fee or end of term charge $ 7,500,000              
Percentage of qualified cash prior to Third performance milestone 60.00%              
Minimum percentage of qualified cash following third performance milestone 35.00%              
Minimum market capitalization amount $ 900,000,000.0              
Percentage of debt funded to be issued as warrants to purchase common stock 2.50%              
Warrants exercise price $ 33.43              
Warrants expire term 7 years              
Warrants expiration date Sep. 17, 2028              
Fair value of warrant liabilities $ 1,300,000              
Debt issuance costs $ 3,100,000              
Loan Agreement | Common Stock                
Debt Instrument [Line Items]                
Warrants issued to purchase shares 74,782              
Loan Agreement | Term Loan                
Debt Instrument [Line Items]                
Term loans aggregate principal amount $ 200,000,000.0              
Payment for facility charge $ 1,250,000              
Debt instrument, facility charge percentage 0.50%              
Debt instrument, maturity date Oct. 01, 2026              
Loan Agreement | Term Loan | Floor Rate                
Debt Instrument [Line Items]                
Debt instrument, basis spread on variable rate 5.50%              
Loan Agreement | Term Loan | Prime Rate                
Debt Instrument [Line Items]                
Debt instrument, basis spread on variable rate 2.25%              
Loan Agreement | Term Loan | Payment In Kind PIK Interest Rate                
Debt Instrument [Line Items]                
Debt instrument, interest rate 3.35%              
Loan Agreement | Term Loans, Aggregate Principal Amount Tranches One                
Debt Instrument [Line Items]                
Term loans aggregate principal amount $ 100,000,000.0              
Loan Agreement | Term Loans, Aggregate Principal Amount Tranches Two                
Debt Instrument [Line Items]                
Term loans aggregate principal amount 50,000,000.0              
Loan Agreement | Term Loans, Aggregate Principal Amount Tranches Three                
Debt Instrument [Line Items]                
Term loans aggregate principal amount 25,000,000.0              
Loan Agreement | Term Loans, Aggregate Principal Amount Tranches Four                
Debt Instrument [Line Items]                
Term loans aggregate principal amount $ 25,000,000.0              
Loan Agreement | Term Loan Advance                
Debt Instrument [Line Items]                
Debt instrument, final payment fee percentage 7.50%              
Debt instrument, final payment fee or end of term charge     $ 7,500,000   7,500,000      
Loan Agreement | Term Loan Advance | Maximum                
Debt Instrument [Line Items]                
Debt instrument, prepayment fee percentage of outstanding principal amount 1.25%              
Hercules and SVB Term Loan                
Debt Instrument [Line Items]                
Term loans aggregate principal amount     100,100,000   100,100,000      
Accrued interest     200,000   200,000      
Interest expense     $ 1,500,000 $ 1,300,000 $ 4,000,000.0 $ 3,300,000